HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,300 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and launched. For more information, please visit: www.hutch-med.com or follow us here on LinkedIn.
Company Details
- Employees
- 668
- Address
- Metropolis Tower, 10 Metropolis Drive, Hung Hom, Level 18,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.hutch-med.com
- Keywords
- Pharmaceutical, Biopharmaceutical, Innovation, Research and Development, Oncology, Hematology, Immunology, Inflammation, Cancer, Targeted Therapy.
- HQ
- Hong Kong
Hutchmed Questions
Hutchmed's website is https://www.hutch-med.com
Hutchmed's LinkedIn profile is https://www.linkedin.com/company/hutchmed
Hutchmed has
668 employees.
View email and phone details for 668
employees at Hutchmed.
Hutchmed's industry is
Biotechnology Research
Hutchmed's top competitors are
Pfizer,
Zai Lab,
Beigene,
Abbvie,
Takeda,
Innovent Biologics,
Astrazeneca,
Bristol Myers Squibb,
Hengrui Pharma,
Novartis.
Hutchmed's categories are Biotechnology Research
